Foundry Partners LLC increased its position in shares of Avanos Medical, Inc. (NYSE:AVNS – Free Report) by 22.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 212,556 shares of the company’s stock after buying an additional 39,068 shares during the period. Foundry Partners LLC owned 0.46% of Avanos Medical worth $4,298,000 as of its most recent filing with the SEC.
A number of other hedge funds have also modified their holdings of the business. Westwood Holdings Group Inc. grew its holdings in shares of Avanos Medical by 70.6% in the second quarter. Westwood Holdings Group Inc. now owns 1,715,039 shares of the company’s stock valued at $43,836,000 after purchasing an additional 709,959 shares during the period. Norges Bank purchased a new stake in shares of Avanos Medical in the fourth quarter valued at about $11,055,000. Goldman Sachs Group Inc. grew its holdings in shares of Avanos Medical by 24.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,998,871 shares of the company’s stock valued at $66,962,000 after purchasing an additional 392,870 shares during the period. Macquarie Group Ltd. grew its holdings in shares of Avanos Medical by 21.4% in the first quarter. Macquarie Group Ltd. now owns 1,987,355 shares of the company’s stock valued at $59,104,000 after purchasing an additional 349,799 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Avanos Medical by 9.8% in the first quarter. Dimensional Fund Advisors LP now owns 3,173,794 shares of the company’s stock valued at $94,387,000 after purchasing an additional 281,958 shares during the period. 93.84% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, TheStreet downgraded shares of Avanos Medical from a “c-” rating to a “d” rating in a research note on Wednesday, November 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $29.50.
Avanos Medical Stock Up 1.8 %
Shares of NYSE:AVNS opened at $19.36 on Tuesday. The company has a current ratio of 3.07, a quick ratio of 2.16 and a debt-to-equity ratio of 0.21. Avanos Medical, Inc. has a twelve month low of $17.24 and a twelve month high of $31.99. The company has a market capitalization of $898.88 million, a PE ratio of -16.27, a P/E/G ratio of 1.11 and a beta of 0.96. The firm has a 50 day simple moving average of $20.44 and a 200-day simple moving average of $20.76.
About Avanos Medical
Avanos Medical, Inc, a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands.
- Five stocks we like better than Avanos Medical
- What is a Dividend King?
- Lowe’s levels up: A blueprint for tomorrow’s home improvement
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Duke Energy stock ready to power up in 2024?
- The How and Why of Investing in Biotech Stocks
- Hershey stock presents investors a sweet buy-the-dip opportunity
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.